89bio Future Growth

Future criteria checks 2/6

89bio is forecast to grow earnings and revenue by 18.3% and 81.8% per annum respectively. EPS is expected to grow by 23.3% per annum. Return on equity is forecast to be -131.1% in 3 years.

Key information

18.3%

Earnings growth rate

23.3%

EPS growth rate

Biotechs earnings growth	28.4%
Revenue growth rate	81.8%
Future return on equity	-131.1%
Analyst coverage	Good
Last updated	13 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGM:ETNB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	26	-287	-320	-318	7
12/31/2025	3	-274	-283	-310	7
12/31/2024	1	-230	-196	-234	7
6/30/2024	N/A	-175	-166	-166	N/A
3/31/2024	N/A	-165	-139	-139	N/A
12/31/2023	N/A	-142	-129	-129	N/A
9/30/2023	N/A	-127	-122	-122	N/A
6/30/2023	N/A	-119	-106	-106	N/A
3/31/2023	N/A	-105	-87	-87	N/A
12/31/2022	N/A	-102	-81	-81	N/A
9/30/2022	N/A	-104	-82	-82	N/A
6/30/2022	N/A	-105	-81	-81	N/A
3/31/2022	N/A	-101	-86	-86	N/A
12/31/2021	N/A	-90	-77	-77	N/A
9/30/2021	N/A	-76	-63	-63	N/A
6/30/2021	N/A	-63	-62	-62	N/A
3/31/2021	N/A	-54	-54	-53	N/A
12/31/2020	N/A	-49	-46	-46	N/A
9/30/2020	N/A	-56	-44	-43	N/A
6/30/2020	N/A	-60	-37	-37	N/A
3/31/2020	N/A	-64	-29	-29	N/A
12/31/2019	N/A	-57	-26	-25	N/A
9/30/2019	N/A	-44	-19	-19	N/A
6/30/2019	N/A	-30	-15	-15	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ETNB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ETNB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ETNB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ETNB's revenue (81.8% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: ETNB's revenue (81.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ETNB is forecast to be unprofitable in 3 years.

89bio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 9.4% to US$33.44

Price target increased by 7.8% to US$37.44

Consensus EPS estimates upgraded to US$2.01 loss

Price target increased by 34% to US$33.75

Price target increased to US$24.63

Consensus forecasts updated

Recent updates

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval

COO & Chief Business Officer exercised options and sold US$104k worth of stock

CEO & Director recently bought US$118k worth of stock

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

COO & Chief Business Officer exercised options and sold US$124k worth of stock

89Bio Initiates Phase 2B Enliven Trial of Bio89-100 for the Treatment of Nash

COO & Chief Business Officer notifies of intention to sell stock

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio, Inc. Announces Additional Positive Data from its Phase 1b/2a Study of BIO89-100 to Be Present at the Annual Endo 2021 Conference